{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:45:16Z","timestamp":1792215916985,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016820","name":"Vaccine Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.immuni.2026.04.011","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:46:07Z","timestamp":1778597167000},"page":"1174-1176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["ART Interrupted: Insights into ART-free HIV remission"],"prefix":"10.1016","volume":"59","author":[{"given":"Ramon A.","family":"Lujan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-4594","authenticated-orcid":false,"given":"Eli A.","family":"Boritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2026.04.011_bib1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.immuni.2026.04.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1003211","article-title":"Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study","volume":"9","author":"Saez-Cirion","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.immuni.2026.04.011_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2026.01.029","article-title":"Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV rebound","volume":"59","author":"Ma","year":"2026","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.04.011_bib4","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(16)30055-8","article-title":"Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B\/2A trial","volume":"3","author":"Leth","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.immuni.2026.04.011_bib5","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"10.1016\/j.immuni.2026.04.011_bib6","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals","volume":"33","author":"Vibholm","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.immuni.2026.04.011_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/jci.insight.173864","article-title":"Predictors of HIV rebound differ by timing of antiretroviral therapy initiation","volume":"9","author":"Li","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.immuni.2026.04.011_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ebiom.2021.103270","article-title":"LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy","volume":"65","author":"Planas","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.immuni.2026.04.011_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41586-025-09932-w","article-title":"CD8(+) T cell stemness precedes post-intervention control of HIV viraemia","volume":"650","author":"Kiani","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.04.011_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41586-025-09929-5","article-title":"Correlates of HIV-1 control after combination immunotherapy","volume":"650","author":"Peluso","year":"2026","journal-title":"Nature"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761326001731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761326001731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:29:27Z","timestamp":1792214967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761326001731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1074761326001731"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2026.04.011","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ART Interrupted: Insights into ART-free HIV remission","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2026.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2026.01.029","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}